MARKET

SMMT

SMMT

Summit Therapeutics Inc
NASDAQ
17.40
-1.02
-5.54%
After Hours: 17.35 -0.05 -0.29% 19:43 09/15 EDT
OPEN
18.16
PREV CLOSE
18.42
HIGH
18.47
LOW
17.11
VOLUME
5.80M
TURNOVER
--
52 WEEK HIGH
29.23
52 WEEK LOW
12.07
MARKET CAP
13.88B
P/E (TTM)
-15.5468
1D
5D
1M
3M
1Y
5Y
1D
Summit Therapeutics Highlights Positive Ivonescimab Phase III Survival Data
TipRanks · 17h ago
Summit Therapeutics Presents Updated Overall Survival Results From Global Phase III HARMIONi Clinical Trial Of Ivonescimab At The International Association For The Study Of Lung Cancer Conference; Sustained OS Improvement Seen With Longer Follow-Up In Western Patients, Consistent Across Geographic Regions; No New Safety Signals Observed
Benzinga · 20h ago
Summit Therapeutics reports updated OS results from Phase 3 Harmoni trial
TipRanks · 20h ago
Why Is Summit Therapeutics Stock Gaining Monday?
Benzinga · 1d ago
Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT) and Azenta (AZTA)
TipRanks · 1d ago
Summit Therapeutics Showcases Promising Ivonescimab Survival Data
TipRanks · 1d ago
At a glance: stocks gapping up premarket
Seeking Alpha · 1d ago
Weekly Report: what happened at SMMT last week (0907-0911)?
Weekly Report · 1d ago
More
About SMMT
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician, caregiver and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. Its lead development candidate is ivonescimab, a novel, potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. Ivonescimab is being developed by both Akeso and the Company in multiple Phase III clinical trials. It is also developing ivonescimab in non-small cell lung cancer and other solid tumor settings. Ivonescimab is approved in China in combination with chemotherapy for patients with EGFR-mutated non-small cell lung cancer whose tumors have progressed following an EGFR-TKI based on the results of the HARMONi-A clinical trial.

Webull offers Summit Therapeutics Inc stock information, including NASDAQ: SMMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SMMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SMMT stock methods without spending real money on the virtual paper trading platform.